Mandate

Vinge advises Hansa Medical in connection with directed share issue

October 24, 2016

The board of directors of Hansa Medical proposes a capital raising through a directed share issue, whereby the company will receive approximately SEK 185 million.

The share issue is directed to selected international specialist investors as well as Swedish institutional and strategic investors. The issue proceeds will primarily be used to finance the development process of the drug candidate IdeS up to an application for market authorization of IdeS for treatment in connection with kidney transplantation. The share issue is fully subscribed for in accordance with agreements executed with the selected investors. Shareholders representing approximately 45 percent of Hansa Medical’s shares and votes have undertaken to vote in favor of the board’s proposal for the share issue at an extraordinary general meeting.

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team consists of Dain Hård Nevonen, Erik Sjöman and Nils Fredrik Dehlin.

Related

Vinge advises Humana in its acquisition of Team Olivia Norge AS

Humana Group ("Humana") strengthens its offering of high-quality care services in Norway as Human Care Holding AS ("Humana Norway") has entered into an agreement to acquire Team Olivia Norge AS for a purchase price of million SEK 341 on a cash- and debt-free basis.
May 17, 2024

Vinge advises Stendörren in connection with issuance of green capital securities and tender offer

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green subordinated and perpetual capital securities in an amount of SEK 300 million (within a framework of SEK 400 million) and its parallel tender offer in respect of its previously issued capital securities.
May 17, 2024

Vinge has advised Stockholm Exergi AB in connection with the conclusion of a permanent carbon removal agreement with Microsoft, the world’s largest to date

Vinge has advised Stockholm Exergi in connection with the conclusion of a permanent carbon removal agreement with Microsoft, covering 3.33 million tonnes of permanent carbon removals from bio-energy with carbon capture and storage (BECCS) at Värtan, Stockholm. The agreement is the world’s largest permanent carbon removal deal to date.
May 16, 2024